Skip to main content
COVID-19

Medical Policy Revision: Identification of Microorganisms Using Nucleic Acid Probes

Effective June 27, 2016, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain claims for the use of nucleic acid testing using a direct or amplified probe technique.

According to the guidelines of our revised medical policy, Identification of Microorganisms Using Nucleic Acid Probes, the use of nucleic acid testing using a direct or amplified probe technique (with or without quantification of viral load) may be considered an investigational service for certain microorganisms.

We encourage you to review this policy in our online Medical Policy Manual.

Based on the guidelines of our medical policy, Identification of Microorganisms Using Nucleic Acid Probes, CPT® code 87582 included on claims for services provided on and after June 27, 2016 will be denied as an investigational service regardless of the submitted diagnosis code(s).

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after June 27, 2016.

CPT® is a registered mark of the American Medical Association.

Published on: March 28, 2016, 07:11 a.m. ET
Last updated on: November 25, 2020, 00:20 a.m. ET